387 related articles for article (PubMed ID: 16932955)
1. Polyfunctional analysis of human t cell responses: importance in vaccine immunogenicity and natural infection.
Makedonas G; Betts MR
Springer Semin Immunopathol; 2006 Nov; 28(3):209-19. PubMed ID: 16932955
[No Abstract] [Full Text] [Related]
2. Antiviral memory T cell responses: correlation with protective immunity and implication for vaccine development.
Harari A; Ellefsen K; Champagne P; Nobile M; Pantaleo G
Adv Exp Med Biol; 2002; 512():155-64. PubMed ID: 12405200
[No Abstract] [Full Text] [Related]
3. Generation and maintenance of human memory cells during viral infection.
Halwani R; Doroudchi M; Yassine-Diab B; Janbazian L; Shi Y; Said EA; Haddad EK; Sékaly RP
Springer Semin Immunopathol; 2006 Nov; 28(3):197-208. PubMed ID: 16967292
[TBL] [Abstract][Full Text] [Related]
4. Subtype AE HIV-1 DNA and recombinant Fowlpoxvirus vaccines encoding five shared HIV-1 genes: safety and T cell immunogenicity in macaques.
De Rose R; Chea S; Dale CJ; Reece J; Fernandez CS; Wilson KM; Thomson S; Ramshaw IA; Coupar BE; Boyle DB; Sullivan MT; Kent SJ
Vaccine; 2005 Mar; 23(16):1949-56. PubMed ID: 15734067
[TBL] [Abstract][Full Text] [Related]
5. Role of cytokines in the development and maintenance of memory T cells during respiratory viral infection.
Tripp RA
Curr Pharm Des; 2003; 9(1):51-9. PubMed ID: 12570674
[TBL] [Abstract][Full Text] [Related]
6. T cell immune responses to HIV-1.
Vasan S; Schlesinger SJ; Arrode G
Front Biosci; 2007 Jan; 12():2330-43. PubMed ID: 17127243
[TBL] [Abstract][Full Text] [Related]
7. Polyfunctional T cell responses are a hallmark of HIV-2 infection.
Duvall MG; Precopio ML; Ambrozak DA; Jaye A; McMichael AJ; Whittle HC; Roederer M; Rowland-Jones SL; Koup RA
Eur J Immunol; 2008 Feb; 38(2):350-63. PubMed ID: 18200635
[TBL] [Abstract][Full Text] [Related]
8. NYVAC immunization induces polyfunctional HIV-specific T-cell responses in chronically-infected, ART-treated HIV patients.
Harari A; Rozot V; Cavassini M; Bellutti Enders F; Vigano S; Tapia G; Castro E; Burnet S; Lange J; Moog C; Garin D; Costagliola D; Autran B; Pantaleo G; Bart PA
Eur J Immunol; 2012 Nov; 42(11):3038-48. PubMed ID: 22930439
[TBL] [Abstract][Full Text] [Related]
9. mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients.
Van Gulck E; Vlieghe E; Vekemans M; Van Tendeloo VF; Van De Velde A; Smits E; Anguille S; Cools N; Goossens H; Mertens L; De Haes W; Wong J; Florence E; Vanham G; Berneman ZN
AIDS; 2012 Feb; 26(4):F1-12. PubMed ID: 22156965
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cell-based therapeutic vaccine elicits polyfunctional HIV-specific T-cell immunity associated with control of viral load.
Lévy Y; Thiébaut R; Montes M; Lacabaratz C; Sloan L; King B; Pérusat S; Harrod C; Cobb A; Roberts LK; Surenaud M; Boucherie C; Zurawski S; Delaugerre C; Richert L; Chêne G; Banchereau J; Palucka K
Eur J Immunol; 2014 Sep; 44(9):2802-10. PubMed ID: 25042008
[TBL] [Abstract][Full Text] [Related]
11. Multiple Approaches for Increasing the Immunogenicity of an Epitope-Based Anti-HIV Vaccine.
Rosa DS; Ribeiro SP; Fonseca SG; Almeida RR; Santana VC; Apostólico Jde S; Kalil J; Cunha-Neto E
AIDS Res Hum Retroviruses; 2015 Nov; 31(11):1077-88. PubMed ID: 26149745
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic immunization for HIV.
Gudmundsdotter L; Sjödin A; Boström AC; Hejdeman B; Theve-Palm R; Alaeus A; Lidman K; Wahren B
Springer Semin Immunopathol; 2006 Nov; 28(3):221-30. PubMed ID: 17031650
[TBL] [Abstract][Full Text] [Related]
13. HIV/AIDS vaccines: 2007.
Robinson HL
Clin Pharmacol Ther; 2007 Dec; 82(6):686-93. PubMed ID: 17971817
[TBL] [Abstract][Full Text] [Related]
14. MVA-nef induces HIV-1-specific polyfunctional and proliferative T-cell responses revealed by the combination of short- and long-term immune assays.
Kutscher S; Allgayer S; Dembek CJ; Bogner JR; Protzer U; Goebel FD; Erfle V; Cosma A
Gene Ther; 2010 Nov; 17(11):1372-83. PubMed ID: 20535218
[TBL] [Abstract][Full Text] [Related]
15. Induction and function of virus-specific CD4+ T cell responses.
Whitmire JK
Virology; 2011 Mar; 411(2):216-28. PubMed ID: 21236461
[TBL] [Abstract][Full Text] [Related]
16. Understanding the mechanisms and limitations of immune control of HIV.
Davenport MP; Ribeiro RM; Zhang L; Wilson DP; Perelson AS
Immunol Rev; 2007 Apr; 216():164-75. PubMed ID: 17367342
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity in macaques of the clinical product for a clade B DNA/MVA HIV vaccine: elicitation of IFN-gamma, IL-2, and TNF-alpha coproducing CD4 and CD8 T cells.
Robinson HL; Sharma S; Zhao J; Kannanganat S; Lai L; Chennareddi L; Yu T; Montefiori DC; Amara RR; Wyatt LS; Moss B
AIDS Res Hum Retroviruses; 2007 Dec; 23(12):1555-62. PubMed ID: 18160013
[TBL] [Abstract][Full Text] [Related]
18. Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial.
Janes HE; Cohen KW; Frahm N; De Rosa SC; Sanchez B; Hural J; Magaret CA; Karuna S; Bentley C; Gottardo R; Finak G; Grove D; Shen M; Graham BS; Koup RA; Mulligan MJ; Koblin B; Buchbinder SP; Keefer MC; Adams E; Anude C; Corey L; Sobieszczyk M; Hammer SM; Gilbert PB; McElrath MJ
J Infect Dis; 2017 May; 215(9):1376-1385. PubMed ID: 28199679
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 Subtype C Mosaic Gag Expressed by BCG and MVA Elicits Persistent Effector T Cell Responses in a Prime-Boost Regimen in Mice.
Jongwe TI; Chapman R; Douglass N; Chetty S; Chege G; Williamson AL
PLoS One; 2016; 11(7):e0159141. PubMed ID: 27427967
[TBL] [Abstract][Full Text] [Related]
20. Development of targeted adjuvants for HIV-1 vaccines.
Liu J; Ostrowski M
AIDS Res Ther; 2017 Sep; 14(1):43. PubMed ID: 28893282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
